Free Trial
→ Is SpaceX really worth 1.78 Trillion? (From InvestPub) (Ad)tc pixel Free FAB Stock Alerts

Fusion Antibodies (FAB) Competitors

Fusion Antibodies logo
GBX 12.38 +0.13 (+1.06%)
As of 11:32 AM Eastern
Compare

FAB vs. HVO, REDX, POLB, ETX, and HEMO

Should you buy Fusion Antibodies stock or one of its competitors? MarketBeat compares Fusion Antibodies with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Fusion Antibodies include hVIVO (HVO), Redx Pharma (REDX), Poolbeg Pharma (POLB), e-therapeutics (ETX), and Hemogenyx Pharmaceuticals (HEMO). These companies are all part of the "biotechnology" industry.

How does Fusion Antibodies compare to hVIVO?

hVIVO (LON:HVO) and Fusion Antibodies (LON:FAB) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, dividends, media sentiment, institutional ownership, valuation, risk, analyst recommendations and earnings.

11.8% of hVIVO shares are held by institutional investors. Comparatively, 7.6% of Fusion Antibodies shares are held by institutional investors. 4.9% of hVIVO shares are held by company insiders. Comparatively, 5.9% of Fusion Antibodies shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

hVIVO has a beta of 1.685, indicating that its stock price is 69% more volatile than the broader market. Comparatively, Fusion Antibodies has a beta of 1.215, indicating that its stock price is 22% more volatile than the broader market.

hVIVO presently has a consensus price target of GBX 15, indicating a potential upside of 75.54%. Given hVIVO's stronger consensus rating and higher possible upside, research analysts plainly believe hVIVO is more favorable than Fusion Antibodies.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
hVIVO
0 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.67
Fusion Antibodies
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

In the previous week, hVIVO's average media sentiment score of 0.00 equaled Fusion Antibodies'average media sentiment score.

Company Overall Sentiment
hVIVO Neutral
Fusion Antibodies Neutral

hVIVO has a net margin of -12.48% compared to Fusion Antibodies' net margin of -91.92%. hVIVO's return on equity of -14.65% beat Fusion Antibodies' return on equity.

Company Net Margins Return on Equity Return on Assets
hVIVO-12.48% -14.65% 11.97%
Fusion Antibodies -91.92%-210.32%-63.78%

hVIVO has higher revenue and earnings than Fusion Antibodies. hVIVO is trading at a lower price-to-earnings ratio than Fusion Antibodies, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
hVIVO£46.77M1.26£17.84M-£0.87N/A
Fusion Antibodies£1.60M9.70-£4.10M-£1.50N/A

Summary

hVIVO beats Fusion Antibodies on 11 of the 14 factors compared between the two stocks.

How does Fusion Antibodies compare to Redx Pharma?

Fusion Antibodies (LON:FAB) and Redx Pharma (LON:REDX) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, dividends, profitability, media sentiment and risk.

Fusion Antibodies has higher earnings, but lower revenue than Redx Pharma. Fusion Antibodies is trading at a lower price-to-earnings ratio than Redx Pharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Fusion Antibodies£1.60M9.70-£4.10M-£1.50N/A
Redx Pharma£4.20M0.00-£33.16M-£0.10N/A

Fusion Antibodies has a beta of 1.215, suggesting that its stock price is 22% more volatile than the broader market. Comparatively, Redx Pharma has a beta of -0.53, suggesting that its stock price is 153% less volatile than the broader market.

7.6% of Fusion Antibodies shares are owned by institutional investors. Comparatively, 72.7% of Redx Pharma shares are owned by institutional investors. 5.9% of Fusion Antibodies shares are owned by company insiders. Comparatively, 18.4% of Redx Pharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Fusion Antibodies' average media sentiment score of 0.00 equaled Redx Pharma'saverage media sentiment score.

Company Overall Sentiment
Fusion Antibodies Neutral
Redx Pharma Neutral

Redx Pharma has a net margin of 0.00% compared to Fusion Antibodies' net margin of -91.92%. Redx Pharma's return on equity of -180.80% beat Fusion Antibodies' return on equity.

Company Net Margins Return on Equity Return on Assets
Fusion Antibodies-91.92% -210.32% -63.78%
Redx Pharma N/A -180.80%-43.95%

Summary

Redx Pharma beats Fusion Antibodies on 7 of the 10 factors compared between the two stocks.

How does Fusion Antibodies compare to Poolbeg Pharma?

Poolbeg Pharma (LON:POLB) and Fusion Antibodies (LON:FAB) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, dividends, risk, profitability, institutional ownership and earnings.

Poolbeg Pharma has a beta of 1.821, indicating that its stock price is 82% more volatile than the broader market. Comparatively, Fusion Antibodies has a beta of 1.215, indicating that its stock price is 22% more volatile than the broader market.

Poolbeg Pharma has a net margin of 0.00% compared to Fusion Antibodies' net margin of -91.92%. Poolbeg Pharma's return on equity of -55.47% beat Fusion Antibodies' return on equity.

Company Net Margins Return on Equity Return on Assets
Poolbeg PharmaN/A -55.47% -21.33%
Fusion Antibodies -91.92%-210.32%-63.78%

1.5% of Poolbeg Pharma shares are held by institutional investors. Comparatively, 7.6% of Fusion Antibodies shares are held by institutional investors. 7.6% of Poolbeg Pharma shares are held by company insiders. Comparatively, 5.9% of Fusion Antibodies shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Fusion Antibodies has higher revenue and earnings than Poolbeg Pharma. Fusion Antibodies is trading at a lower price-to-earnings ratio than Poolbeg Pharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Poolbeg PharmaN/AN/A-£4.50B-£0.94N/A
Fusion Antibodies£1.60M9.70-£4.10M-£1.50N/A

In the previous week, Poolbeg Pharma had 3 more articles in the media than Fusion Antibodies. MarketBeat recorded 3 mentions for Poolbeg Pharma and 0 mentions for Fusion Antibodies. Fusion Antibodies' average media sentiment score of 0.00 beat Poolbeg Pharma's score of -0.41 indicating that Fusion Antibodies is being referred to more favorably in the news media.

Company Overall Sentiment
Poolbeg Pharma Neutral
Fusion Antibodies Neutral

Summary

Poolbeg Pharma beats Fusion Antibodies on 8 of the 12 factors compared between the two stocks.

How does Fusion Antibodies compare to e-therapeutics?

Fusion Antibodies (LON:FAB) and e-therapeutics (LON:ETX) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, valuation, dividends, analyst recommendations, profitability, media sentiment, institutional ownership and earnings.

7.6% of Fusion Antibodies shares are held by institutional investors. Comparatively, 26.5% of e-therapeutics shares are held by institutional investors. 5.9% of Fusion Antibodies shares are held by insiders. Comparatively, 59.4% of e-therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

e-therapeutics has a net margin of 0.00% compared to Fusion Antibodies' net margin of -91.92%. e-therapeutics' return on equity of -38.75% beat Fusion Antibodies' return on equity.

Company Net Margins Return on Equity Return on Assets
Fusion Antibodies-91.92% -210.32% -63.78%
e-therapeutics N/A -38.75%-29.10%

Fusion Antibodies has a beta of 1.215, meaning that its share price is 22% more volatile than the broader market. Comparatively, e-therapeutics has a beta of 0.46, meaning that its share price is 54% less volatile than the broader market.

In the previous week, Fusion Antibodies' average media sentiment score of 0.00 equaled e-therapeutics'average media sentiment score.

Company Overall Sentiment
Fusion Antibodies Neutral
e-therapeutics Neutral

Fusion Antibodies has higher revenue and earnings than e-therapeutics. Fusion Antibodies is trading at a lower price-to-earnings ratio than e-therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Fusion Antibodies£1.60M9.70-£4.10M-£1.50N/A
e-therapeutics£295K0.00-£10.06M-£0.02N/A

Summary

e-therapeutics beats Fusion Antibodies on 6 of the 10 factors compared between the two stocks.

How does Fusion Antibodies compare to Hemogenyx Pharmaceuticals?

Hemogenyx Pharmaceuticals (LON:HEMO) and Fusion Antibodies (LON:FAB) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, dividends, analyst recommendations, risk, media sentiment and valuation.

Hemogenyx Pharmaceuticals has a net margin of 0.00% compared to Fusion Antibodies' net margin of -91.92%. Fusion Antibodies' return on equity of -210.32% beat Hemogenyx Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Hemogenyx PharmaceuticalsN/A -2,807.75% -37.79%
Fusion Antibodies -91.92%-210.32%-63.78%

Hemogenyx Pharmaceuticals has higher earnings, but lower revenue than Fusion Antibodies. Fusion Antibodies is trading at a lower price-to-earnings ratio than Hemogenyx Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Hemogenyx PharmaceuticalsN/AN/A-£6.89K-£170.60N/A
Fusion Antibodies£1.60M9.70-£4.10M-£1.50N/A

In the previous week, Hemogenyx Pharmaceuticals had 2 more articles in the media than Fusion Antibodies. MarketBeat recorded 2 mentions for Hemogenyx Pharmaceuticals and 0 mentions for Fusion Antibodies. Hemogenyx Pharmaceuticals' average media sentiment score of 0.00 equaled Fusion Antibodies'average media sentiment score.

Company Overall Sentiment
Hemogenyx Pharmaceuticals Neutral
Fusion Antibodies Neutral

Hemogenyx Pharmaceuticals has a beta of 1.496, indicating that its share price is 50% more volatile than the broader market. Comparatively, Fusion Antibodies has a beta of 1.215, indicating that its share price is 22% more volatile than the broader market.

0.2% of Hemogenyx Pharmaceuticals shares are held by institutional investors. Comparatively, 7.6% of Fusion Antibodies shares are held by institutional investors. 10.0% of Hemogenyx Pharmaceuticals shares are held by insiders. Comparatively, 5.9% of Fusion Antibodies shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Hemogenyx Pharmaceuticals beats Fusion Antibodies on 7 of the 11 factors compared between the two stocks.

Get Fusion Antibodies News Delivered to You Automatically

Sign up to receive the latest news and ratings for FAB and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding FAB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

FAB vs. The Competition

Export
MetricFusion AntibodiesBiotechnology IndustryMedical SectorLON Exchange
Market Cap£15.48M£445.14M£6.49B£2.79B
Dividend YieldN/A3.86%2.67%6.13%
P/E Ratio-8.253.1723.85366.76
Price / Sales9.706,480.29572.2486,680.88
Price / Cash9.0213.1343.2027.87
Price / Book3.5289.0310.667.84
Net Income-£4.10M-£96.07M£3.56B£5.89B
7 Day Performance2.74%-1.45%0.05%-0.05%
1 Month Performance-17.47%-0.58%0.37%2.05%
1 Year Performance78.13%51.42%22.73%75.16%

Fusion Antibodies Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
FAB
Fusion Antibodies
N/AGBX 12.38
+1.1%		N/A+71.8%£15.48M£1.60MN/A48
HVO
hVIVO
1.9025 of 5 stars		GBX 8.80
-0.2%		GBX 15
+70.5%		-29.5%£60.58M£46.77MN/AN/A
REDX
Redx Pharma
N/AN/AN/AN/A£58.35M£4.20MN/A101
POLB
Poolbeg Pharma
N/AGBX 8.12
-5.6%		N/A+126.1%£57.22MN/AN/A12
ETX
e-therapeutics
N/AN/AN/AN/A£52.59M£295KN/A35

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (LON:FAB) was last updated on 6/12/2026 by MarketBeat.com Staff.
From Our Partners
Do NOT Buy SpaceX – Do This Instead
SpaceX is set to go public as soon as June 11, with OpenAI and Anthropic likely to follow. Whitney Tilson - Ha...
Stansberry Research | Sponsoredtc pixel
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
There’s a new type of capitalism
The U.S. government has taken direct equity positions in at least 10 companies - Intel, U.S. Steel, Westinghou...
Porter & Company | Sponsoredtc pixel
How to play the Biggest IPO in stock market history!
SpaceX is eyeing a near-$2 trillion IPO valuation, and retail investors are already lining up - but early insi...
InvestPub | Sponsoredtc pixel
BUY THIS: Claim a backdoor stake in SpaceX
There may be a way to claim pre-IPO exposure to SpaceX before it ever hits public markets - using a simple tra...
Chaikin Analytics | Sponsoredtc pixel
Tesla. SolarCity. Twitter. This $4 stock is next.
Elon Musk has a clear pattern: when a supplier becomes mission-critical, he acquires it. He bought SolarCity f...
Behind the Markets | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
This Is How Financial Freedom Dies—And Most People Never See It Coming
While the trade war grabs headlines, the Department of Justice has quietly argued in court that cash may not b...
Priority Gold | Sponsoredtc pixel